Clinical Trial Update: A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole [Phase 2]

View source ↗

Summary

Phase 2 trial comparing X842 to lansoprazole for safety, tolerability, and healing of erosive esophagitis over 4 weeks, with a subsequent 4 weeks of lansoprazol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erosive Esophagitis

Drugs mentioned

• Lansoprazole (Lansoprazole)
• X842

Snippet

Sponsor: Cinclus Pharma AG | Conditions: Erosive Esophagitis | Phase 2 | Status: COMPLETED | Results posted: 2023-11-01